A new type of treatment for osteoarthritis, currently in canine clinical trials, shows promise for eventual use in humans.
The treatment, developed by Cornell biomedical engineers, is a synthetic version of a naturally occurring joint lubricant that binds to the surface of cartilage in joints and acts as a cushion during high-impact activities, such as running.
“When the production of that specific lubricant goes down, it creates higher contact between the surfaces of the joint and, over time, it leads to osteoarthritis,” said David Putnam, a professor in the College of Engineering with appointments in the Meinig School of Biomedical Engineering and the Smith School of Chemical and Biomolecular Engineering.
Putnam is senior author of “Boundary Mode Lubrication of Articular Cartilage With a Biomimetic Diblock Copolymer,” published June 4 in Proceedings of the National Academy of Sciences, USA. Zhexun Sun, a postdoctoral researcher in Putnam’s lab, is the paper’s first author.
The study focuses on a naturally occurring joint lubricant called lubricin, the production of which declines following traumatic injuries to a joint, such as a ligament tear in a knee.
The knee is lubricated in two ways – hydrodynamic mode and boundary mode.
Hydrodynamic mode lubrication occurs when the joint is moving fast and there isn’t a strong force pushing down on it. In this mode, joints are lubricated by compounds like hyaluronic acid (HA) that are thick and gooey, like car oil. There are numerous HA products on the market, approved by the Food and Drug Administration, for treating hydrodynamic mode lubrication disorders.
But HA is ineffective when strong forces are pushing down on the joint, such as those that occur during running or jumping. In these instances, thick gooey HA squirts out from between the cartilage surfaces, and boundary mode lubrication is necessary. Under these forces, lubricin binds to the surface of the cartilage. It contains sugars that hold on to water, to cushion hard forces on the knee.
In the paper, the researchers describe a synthetic polymer they developed that mimics the function of lubricin and is much easier to produce. “We are in clinical trials, with dogs that have osteoarthritis, with our collaborators at Cornell’s College of Veterinary Medicine,” Putnam said.
Those collaborators – Ursula Krotscheck and Kei Hayashi, both associate professors in the Section of Small Animal Surgery in the Department of Clinical Sciences – use a force plate to measure the efficacy of the treatments. The force plate quantifies the amount of force that a dog exerts with each paw, to measure whether they are favoring one paw over another.
“Once we finalize the efficacy study in dogs, we will be in a very good position to market the material for veterinary osteoarthritis treatment,” Putnam said. From there, the human market for a lubricin substitute should follow, just as HA has been made available for human use, mainly in knees.
The Latest on: Osteoarthritis
via Google News
The Latest on: Osteoarthritis
- Spine Osteoarthritis Industry & Technological Innovation: Major Players Hitting the Reset Button | Novartis, ABIOGEN PHARMA, Strykeron June 2, 2020 at 9:31 pm
Latest released the research study on Global Spine Osteoarthritis Market, offers a detailed overview of the factors influencing the global business scope. Spine Osteoarthritis Market research report ...
- Dextrose injections aid knee osteoarthritis painon June 2, 2020 at 5:02 am
(HealthDay)—Intra-articular dextrose prolotherapy (DPT) injections are a safe and effective treatment for knee osteoarthritis, according to a study published in the May/June issue of the Annals of ...
- Study highlights potential benefits of new drug for inflammatory diseaseson June 1, 2020 at 2:16 pm
New research conducted by the University of Liverpool and AKL Research and Development Ltd, published in Inflammopharmacology, highlights the potential benefits of a new drug treatment on the human ...
- COVID – 19 Impact Osteoarthritis Market to Register CAGR 4.8% Growth in Value Share During 2025on May 27, 2020 at 7:28 am
(Market Insight Reports) -- The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for ...
- Global cases of hip, knee osteoarthritis exceed 300 millionon May 26, 2020 at 2:08 pm
There were more than 300 million cases of hip and knee osteoarthritis reported worldwide in 2017, with figures expected to rise even further in the future, particularly among women, according to data ...
- Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritison May 22, 2020 at 6:00 am
Samumed, LLC, announced today the publication of results from the Phase 2a trial of lorecivivint, an investigational CLK/DYRK1A inhibitor that modulates the Wnt pathway, for the potential treatment of ...
- Biomechanical footwear system reduces pain in knee osteoarthritison May 14, 2020 at 1:43 pm
Patients with knee osteoarthritis experienced improved pain at 24 weeks after wearing specially designed footwear affixed with individually calibrated convex pods on the outsoles, according to ...
- The number of people with osteoarthritis worldwide is on the riseon May 12, 2020 at 4:30 pm
The prevalence and incidence of osteoarthritis represent a growing burden worldwide that is only expected to increase, according to an analysis of the Global Burden of Diseases, Injuries ...
- Special footwear might reduce pain from knee osteoarthritis, study findson May 12, 2020 at 2:57 pm
Specially designed shoes can help reduce the pain of knee osteoarthritis, a study published Tuesday by JAMA has found.
- Global Osteoarthritis Industry, Pipeline, Epidemiology, Competition, Drug Sales and Shares 2016-2024on May 12, 2020 at 7:17 am
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
via Bing News